Targeted protein degradation combines the power of eliminating a disease-causing protein with the advantages of small molecule circulation in the body. Kymera is pioneering and advancing this technology by designing novel heterobifunctional molecules that engage the target protein and the E3 ligases, to direct the target protein to be selectively degraded by the ubiquitin-proteasome system. We have utilized this technology to successfully degrade several protein targets of disease interest. This talk will describe the investigation of the pharmacology of degraders, and the use of degraders and small molecule inhibitors to elucidate the multiple roles of proteins in signaling pathways, that can lead to distinct functional outcomes.

Use of heterobifunctional molecules that direct targeted protein degradation to explore signaling pathways

2019 Spring National Meeting

The official archive and repository for all ACS Meetings & Expositions abstracts and select posters or presentations.